Shannon C Walker1, C Buddy Creech2,3, Henry J Domenico4, Benjamin French4, Daniel W Byrne4, Allison P Wheeler5,6. 1. Divisions of Pediatric Hematology and Oncology, shannon.walker@vumc.org. 2. Pediatric Infectious Diseases, and. 3. Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Biostatistics, and. 5. Divisions of Pediatric Hematology and Oncology. 6. Pathology, Microbiology, and Immunology.
Abstract
BACKGROUND: Hospital-associated venous thromboembolism (HA-VTE) is an increasing cause of morbidity in pediatric populations, yet identification of high-risk patients remains challenging. General pediatric models have been derived from case-control studies, but few have been validated. We developed and validated a predictive model for pediatric HA-VTE using a large, retrospective cohort. METHODS: The derivation cohort included 111 352 admissions to Monroe Carell Jr. Children's Hospital at Vanderbilt. Potential variables were identified a priori, and corresponding data were extracted. Logistic regression was used to estimate the association of potential risk factors with development of HA-VTE. Variable inclusion in the model was based on univariate analysis, availability in routine medical records, and clinician expertise. The model was validated by using a separate cohort with 44 138 admissions. RESULTS: A total of 815 encounters were identified with HA-VTE in the derivation cohort. Variables strongly associated with HA-VTE include history of thrombosis (odds ratio [OR] 8.7; 95% confidence interval [CI] 6.6-11.3; P < .01), presence of a central line (OR 4.9; 95% CI 4.0-5.8; P < .01), and patients with cardiology conditions (OR 4.0; 95% CI 3.3-4.8; P < .01). Eleven variables were included, which yielded excellent discriminatory ability in both the derivation cohort (concordance statistic = 0.908) and the validation cohort (concordance statistic = 0.904). CONCLUSIONS: We created and validated a risk-prediction model that identifies pediatric patients at risk for HA-VTE development. We anticipate early identification of high-risk patients will increase prophylactic interventions and decrease the incidence of pediatric HA-VTE.
BACKGROUND: Hospital-associated venous thromboembolism (HA-VTE) is an increasing cause of morbidity in pediatric populations, yet identification of high-risk patients remains challenging. General pediatric models have been derived from case-control studies, but few have been validated. We developed and validated a predictive model for pediatric HA-VTE using a large, retrospective cohort. METHODS: The derivation cohort included 111 352 admissions to Monroe Carell Jr. Children's Hospital at Vanderbilt. Potential variables were identified a priori, and corresponding data were extracted. Logistic regression was used to estimate the association of potential risk factors with development of HA-VTE. Variable inclusion in the model was based on univariate analysis, availability in routine medical records, and clinician expertise. The model was validated by using a separate cohort with 44 138 admissions. RESULTS: A total of 815 encounters were identified with HA-VTE in the derivation cohort. Variables strongly associated with HA-VTE include history of thrombosis (odds ratio [OR] 8.7; 95% confidence interval [CI] 6.6-11.3; P < .01), presence of a central line (OR 4.9; 95% CI 4.0-5.8; P < .01), and patients with cardiology conditions (OR 4.0; 95% CI 3.3-4.8; P < .01). Eleven variables were included, which yielded excellent discriminatory ability in both the derivation cohort (concordance statistic = 0.908) and the validation cohort (concordance statistic = 0.904). CONCLUSIONS: We created and validated a risk-prediction model that identifies pediatric patients at risk for HA-VTE development. We anticipate early identification of high-risk patients will increase prophylactic interventions and decrease the incidence of pediatric HA-VTE.
Authors: Christopher R Connelly; Amy Laird; Jeffrey S Barton; Peter E Fischer; Sanjay Krishnaswami; Martin A Schreiber; David H Zonies; Jennifer M Watters Journal: JAMA Surg Date: 2016-01 Impact factor: 14.766
Authors: Riten Kumar; Vilmarie Rodriguez; Jane M S Matsumoto; Shakila P Khan; Amy L Weaver; Robert D McBane; Timothy J Beebe; John A Heit Journal: Thromb Res Date: 2014-12-05 Impact factor: 3.944
Authors: Rachel M Landisch; Sheila J Hanson; Laura D Cassidy; Kristin Braun; Rowena C Punzalan; David M Gourlay Journal: J Trauma Acute Care Surg Date: 2017-05 Impact factor: 3.313
Authors: Brandon A Sherrod; Samuel G McClugage; Vincent E Mortellaro; Inmaculada B Aban; Brandon G Rocque Journal: J Pediatr Surg Date: 2018-10-10 Impact factor: 2.545